Melhores Mieloma médicos em Israel - TOP-18 médicos

O Professor Ron Ram atua no Sourasky Medical Center (Ichilov), o maior hospital universitário de Israel.

• O colega Professor Fredi Aviv chefia a Unidade de Transplante de Medula Óssea no local
• A equipe é especializada em cânceres hematológicos, incluindo mieloma
• Utilizar tratamentos avançados, como imunoterapia celular
• O centro é líder em pesquisas de transplante autólogo de células-tronco

O Dr. Ron Ram realizou centenas de transplantes de células estaminais no Sourasky Medical Center – um procedimento fundamental para o tratamento do Mieloma.

• Certificado em Medicina Interna, Hematologia e Oncologia Médica
• Publicar mais de 30 artigos científicos e um capítulo de livro sobre hematologia
• Concluir a sua especialização em Hematologia e Oncologia no New York Medical College
• Oferecer uma abordagem individualizada para cada paciente de transplante

A Dra. El Hasid realizou mais de 300 transplantes de medula óssea e sangue do cordão umbilical em crianças. Ela chefia o Departamento de Onco-hematologia e Oncologia Pediátrica do Hospital Infantil Dana Dwek.

• Especializar-se em transplante pediátrico de medula óssea e sangue umbilical
• Ser membro da Associação Americana de Hematologia
• Ser membro da Sociedade Israelense de Hemato-oncologia Pediátrica
• Realizar formação no renomado Hospital City of Hope, em Los Angeles
• Escrever 50 publicações e 40 relatórios de conferências

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

O Dr. Michael Shapira é um hematologista sênior conhecido por provar que a idade não é uma barreira para o sucesso dos transplantes de células-tronco. Ele lidera a Unidade de Internação de Hematologia e o Hospital de Dia no Tel Aviv Sourasky Medical Center.

• Especializar-se em transplante de medula óssea para pacientes idosos
• Tratar a doença do enxerto contra o hospedeiro (GVHD)
• Anteriormente médico sênior no Departamento de Transplante de Células-Tronco do Hospital Hadassah Ein Kerem
• Ser membro de várias associações médicas internacionais
• Graduar-se na faculdade de medicina da Universidade Hebraica de Jerusalém

O Dr. Fredi Aviv dedica-se ao Mieloma há 31 anos no principal Centro Médico Sourasky de Tel Aviv.

• Especializar-se como onco-hematologista, tratando especificamente cancros do sangue
• Ter vasta experiência na gestão de protocolos complexos de tratamento de cancro do sangue
• Trabalhar num dos centros médicos mais proeminentes e abrangentes de Israel

O Dr. Dror Levin é um renomado especialista em distúrbios sanguíneos pediátricos e câncer ósseo, dirigindo o departamento de hemato-oncologia pediátrica do Sourasky Medical Center.

• Especializar-se no tratamento de câncer ósseo (sarcoma) em crianças
• Membro da associação israelense de hemato-oncologia pediátrica (ISPHO)
• Formar-se no Instituto Ortopédico Rizzoli, na Itália – líder mundial em oncologia óssea
• Coordenar o tratamento de distúrbios de coagulação sanguínea em crianças

O Dr. Kirshner participa ativamente de pesquisas sobre mieloma e ensaios clínicos, incluindo ensaios de fase III que testam novas combinações de tratamento.

• Formação especializada (Fellowship) em hematologia e oncologia médica no Montefiore Medical Center
• Especializar-se em abordagens de tratamento avançadas para o mieloma
• Longa experiência de trabalho no prestigiado Sourasky Medical Center
• Certificação em medicina interna e oncologia

O Dr. Yair é um hematologista premiado no Sourasky Medical Center, especializado em cancros do sangue, como o mieloma.

• Diversas bolsas de investigação e prémios por contribuições para a hematologia
• Membro das Associações de Hematologia de Israel e Americana
• Formação extensiva em hematologia no Tel Aviv Medical Center

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

A Professora Ben-Yehuda é Chefe de Hematologia do Hadassah Medical Center e reconhecida Decana da sua Faculdade de Medicina.

• Mais de 30 anos de experiência no tratamento de doenças sanguíneas malignas, incluindo mieloma
• Formação no prestigiado Memorial Sloan-Kettering Cancer Center, em Nova Iorque
• Especialização em transplante de medula óssea e terapia génica avançada
• Liderança em investigação em diagnóstico molecular para doenças hematológicas
• Detentora do prémio Healing with the Heart por cuidados excepcionais ao paciente

O onco-hematologista Ofer Spielberg trata cancros do sangue no Assuta Medical Center.

• Especializar-se exclusivamente no tratamento de mieloma e outros distúrbios sanguíneos
• Trabalhar numa importante rede hospitalar israelita conhecida pela oncologia avançada

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.